<DOC>
	<DOCNO>NCT01087697</DOCNO>
	<brief_summary>The purpose study see Neo-Urinary Conduit ( NUC ) , make laboratory combination patient 's cell material use form conduit safety allow urine flow kidney outside body radical cystectomy patient bladder cancer .</brief_summary>
	<brief_title>Incontinent Urinary Diversion Using Autologous Neo-Urinary Conduit</brief_title>
	<detailed_description>The NUC investigation regenerative medicine product comprise patient 's smooth muscle cell , procure fat biopsy . Tengion develop appropriate culture condition reproducibly generate necessary quantity SMC vitro autologous adipose tissue biopsy . The NUC produce Tengion 's Good Manufacturing Practices ( GMP ) qualify clinical production facility . In process , smooth muscle cell ( SMC ) obtain adipose tissue biopsy propagate ex-vivo approximately 3 - 4 week . At end process , SMCs seed onto surface biodegradable PGA/PLGA mesh scaffold form NUC . The NUC ship investigative site surgical implantation . Over time , NUC facilitate regeneration urinary tract tissue .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>Male female subject 18 80 year age Patients undergoing radical cystectomy treatment bladder cancer clinically stag great T2 , N0 Indicated agree physician investigator patient incontinent conduit diversion mechanism choice post cystectomy History cancer within past 5 year ( except non metastatic prostate non melanoma skin cancer ) Evidence cancer metastasis History pelvic radiation nonpelvic radiation within past 5 year Debilitating cardiac pulmonary disease Expected need chemotherapy within 3 month post cystectomy Life expectancy le 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>bladder cancer</keyword>
	<keyword>radical cystectomy</keyword>
	<keyword>incontinent urinary diversion</keyword>
</DOC>